D-2-hydroxyglutarate supports a tolerogenic phenotype with lowered major histocompatibility class II expression in non-malignant dendritic cells and acute myeloid leukemia cells

URN to cite this document:: urn:nbn:de:bvb:355-epub-553902
DOI to cite this document:: 10.5283/epub.55390

Hammon, Kathrin ; Renner, Kathrin ; Althammer, Michael ; Voll, Florian ; Babl, Nathalie ; Decking, Sonja-Maria ; Siska, Peter J.

; Matos, Carina ; Conejo, Zugey Elizabeth Cárdenas ; Mendes, Karina

; Einwag, Friederike ; Siegmund, Heiko ; Iberl, Sabine ; Berger, Raffaela S.

; Dettmer, Katja ; Schoenmehl, Rebecca ; Brochhausen, Christoph

; Herr, Wolfgang ; Oefner, Peter J.

; Rehli, Michael

; Thomas, Simone

; Kreutz, Marina

License: Creative Commons Attribution Non-commercial 4.0
PDF - Published Version
(3MB)

Date of publication of this fulltext: 23 Jan 2024 09:47

Alternative links to fulltext:Pubmed DOI Publisher

Details

Preview

Export bibliographical data

Abstract

D-2-hydroxyglutarate (D-2-HG) accumulates in primary acute myeloid leukemia (AML) patients with mutated isocitrate dehydrogenase (IDH) and other malignancies. D-2-HG suppresses antitumor T cell immunity but little is known about potential effects on non-malignant myeloid cells. Here we show that D-2-HG impairs human but not murine dendritic cell (DC) differentiation, resulting in a tolerogenic ...